Overview
Based in Leuven, Belgium, Rewind Therapeutics focuses on re-initiating remyelination processes to repair the myelin sheath that protects nerves in major debilitating diseases. The company leverages decades of research expertise and a strong patent estate to develop novel remyelination therapeutics, backed by top-tier life science investors including Boehringer Ingelheim Venture Fund and M-Ventures.
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.